Products for Research Use Only

LCMV gp33-41 (TFA)

CAT: 0804-HY-P1569A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P1569A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LCMV gp33-41 (TFA), the carboxyl-extended 11-aa-long peptide, is an lymphocytic choriomeningitis virus sequence restricted by MHC class I H-2Db molecules and presented to cytotoxic T lymphocytes[1].
UNSPSC
12352209
Target
Arenavirus
Type
Peptides
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/lcmv-gp33-41-tfa.html
Purity
98.52
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCSC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCCCN)N.O=C(O)C(F)(F)F
Molecular Formula
C50H74N11F3015S
Molecular Weight
1158.24
References & Citations
[1]Gairin JE, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69 (4) :2297-305.|[2]Smyth M, et al., Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus. Front Immunol. 2021 Jun 14;12:638485.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported

Popular Products